An experimental drug being developed by Swiss drug manufacturer Roche Holding AG has shown the ability to significantly increase the survivability of non-small-cell lung cancer patients.
An experimental drug being developed by Swiss drug manufacturer Roche Holding AG has shown the ability to significantly increase the survivability of non-small-cell lung cancer patients.